The societal role of lifelong vaccination

The full economic and societal value of vaccination is complex to assess. Although direct protection is the immediate goal of vaccination programmes, it is rare that 100% uptake is attained. An important facet of vaccines value comes from the indirect (or herd) protection they provide. The evolving dynamics of our society, including the increase in the proportion of older individuals enhances the value of indirect protection in reducing disease transmission within the family setting and the society as a whole. For example, grandparents are increasingly involved in childcare, putting them at risk of disease transmission if they or the children are not vaccinated. Preventing disease in children can also reduce absenteeism for parents who otherwise would take days off work to care for their sick children, leading to a substantial societal burden. Preventing disease in working adults reduces absenteeism and presenteeism, enhancing productivity and contributing in turn to economic growth. Quality of life is essential at all ages. It is fundamental in children for their life chances, educational achievements, and healthy wellbeing. Additionally, preventing common diseases in adults and the elderly also contributes to their quality of life and helps to assure healthy ageing for growing ageing populations. These wider economic and societal values, although difficult to measure, should be taken into consideration in assessments of the economic value and cost-effectiveness of vaccination programmes.

[1]  C. Signorelli,et al.  Role of vaccination in economic growth , 2015, Journal of market access & health policy.

[2]  T. Szucs,et al.  From population to public institutions: what needs to be changed to benefit from the full value of vaccination , 2015, Journal of market access & health policy.

[3]  S. Carroll,et al.  Challenges in quantifying the patient-reported burden of herpes zoster and post-herpetic neuralgia in the UK: learnings from the Zoster Quality of Life (ZQOL) study , 2013, BMC Research Notes.

[4]  T. Heikkinen,et al.  Burden of paediatric influenza in Western Europe: a systematic review , 2012, BMC Public Health.

[5]  S. Carroll,et al.  PSY34 Understanding Disease Presentation and Patient-Reported and Economic Impact of Herpes Zoster (HZ) and Post-Herpetic Neuralgia (PHN): Findings From the Zoster Quality of Life (ZQOL) Study , 2012 .

[6]  K. Schmader,et al.  Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. , 2012, Vaccine.

[7]  S. Carroll,et al.  PIH45 Burden of Herpes Zoster and Post-Herpetic Neuralgia: Findings from a Cross-Sectional Patient Reported Outcomes Study , 2011 .

[8]  D. Bamford,et al.  An empirical investigation into health sector absenteeism , 2011, Health services management research.

[9]  S. Carroll,et al.  Paediatric hospital admissions for rotavirus gastroenteritis and infectious gastroenteritis of all causes in England: an analysis of correlation with deprivation , 2011, Current medical research and opinion.

[10]  M. Postma,et al.  Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines , 2010, BMJ : British Medical Journal.

[11]  C. Giaquinto,et al.  Impact of community-acquired paediatric rotavirus gastroenteritis on family life: data from the REVEAL study , 2010, BMC family practice.

[12]  P. Bonanni,et al.  Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases. , 2008, Vaccine.

[13]  M. Rose,et al.  Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects , 2008, The European Journal of Health Economics.

[14]  F. Huet,et al.  Burden of paediatric rotavirus gastroenteritis and potential benefits of a universal rotavirus vaccination programme with RotaTeq in France. , 2007, Vaccine.

[15]  J. Heyse,et al.  Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. , 2006, The New England journal of medicine.

[16]  S. Wagenpfeil,et al.  The burden of varicella in Germany , 2004, The European Journal of Health Economics, formerly: HEPAC.

[17]  J. Ehreth The global value of vaccination. , 2003, Vaccine.

[18]  S. Wagenpfeil,et al.  The burden of varicella in Germany. Potential risks and economic impact. , 2004, The European journal of health economics : HEPAC : health economics in prevention and care.

[19]  C. Giaquinto,et al.  Varicella vaccination in Italy : an economic evaluation of different scenarios. , 2004, PharmacoEconomics.

[20]  Heather Joshi,et al.  Millennium Cohort Study First Survey: A User’s Guide to Initial Findings , 2004 .

[21]  P. Beutels Economic evaluation of vaccination programmes in humans: a methodological exploration with applications to hepatitis B, varicella-zoster, measles, pertussis, hepatitis A and pneumococcal vaccination , 2002 .

[22]  M. Guay,et al.  Burden of chickenpox on families: A study in Quebec. , 2001, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.

[23]  T. Lewins,et al.  Fit for purpose , 2000 .